Key facts
- It has raised $1.9M; the latest was Early Stage VC in Jun 2025.
- Notable investors include Ducera Growth Ventures, Arar Capital, Baraúna Investimentos, Calcário Cazanga - Mineração João Vaz Sobrinho, Corteva — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Symbiomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Symbiomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Symbiomics
Operator of a biotechnology company intended to focus on developing biological products containing efficient microbes for multiple applications in agriculture and the environment. The company's services include translating cutting-edge scientific knowledge into products that improve plant performance and reduce environmental degradation, performing notable work, and becoming a global reference in the biological market by developing innovative products and technologies, enabling farmers to do sustainable agricultural production through the use of organic products.
- Sector
- Materials and Resources
- HQ
- Florianópolis, Brazil
- Founded
- 2021
- Employees
- 21
- Website
- symbiomics.com.br/
- Ownership
- Privately Held (backing)
Symbiomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Symbiomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Symbiomics in its N-PORT filings yet. We sweep new filings monthly.